Summit Securities Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Summit Securities Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-531	Closed	-$19.9M	–	442
2019 Q4	$19.9M	Buy	+531	New	+$179K	1.51%	12
2019 Q1	–	Sell	-25	Closed	-$934K	–	325
2018 Q4	$934K	Buy	+25	New	+$9.15K	0.08%	145
2018 Q3	–	Sell	-30	Closed	-$1.03M	–	252
2018 Q2	$1.03M	Buy	30 +5	+20%	+$1.56K	0.15%	81
2018 Q1	$861K	Buy	+25	New	+$8.7K	0.21%	63
2017 Q4	–	Sell	-38	Closed	-$1.7M	–	242
2017 Q3	$1.7M	Buy	+38	New	+$18.1K	0.29%	41

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Summit Securities Group's REGN Position: Q1 2026 in Review

Summit Securities Group reduced its Regeneron Pharmaceuticals (REGN) stake by 55% in Q1 2026, selling an estimated $130K and leaving 138 shares worth $107K. The position accounts for 0.01% of the portfolio, ranked #282.

Summit Securities Group first reported a position in REGN in Q1 2022 and has held it in 10 quarters since. The position peaked at $336K in Q1 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Summit Securities Group held 138 shares of Regeneron Pharmaceuticals worth $107K as of Q1 2026.
Summit Securities Group sold 170 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $130K.
Regeneron Pharmaceuticals made up 0.01% of Summit Securities Group's portfolio in Q1 2026, its #282 holding.
Summit Securities Group first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
Summit Securities Group's Regeneron Pharmaceuticals position peaked at $336K in Q1 2022.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.